Effect of blockage of the endocannabinoid system by CB1 antagonism on cardiovascular risk

Pharmacological Reports

Volumn 61, Issue 1, 2009, Pages 13-21

  Mach, François ^a   Montecucco, Fabrizio ^a   Steffens, Sabine ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cardiovascular risk; Endocannabinoids; Rimonabant

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; METFORMIN; PLACEBO; RIMONABANT; SULFONYLUREA;

ANXIETY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE MODEL; DIZZINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; LOW CALORY DIET; MEDICAL RESEARCH; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; RISK FACTOR; SIDE EFFECT;

EID: 66949122760     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70003-9     Document Type: Conference Paper

References (41)

1. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertáler L et al.: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation, 2004, 110, 1996-2002.
2. Bátkai S, Rajesh M, Mukhopadhyay P, Haskó G, Liaudet L, Cravatt BF, Csiszár A et al.: Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol, 2007, 293, H909-918.
3. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G: Evidence for novel cannabinoid receptors. Pharmacol Ther, 2005, 106, 133-145.
4. Braud S, Bon C, Touqui L, Mounier C: Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett, 2000, 471, 12-16.
5. Chudek J, Wiecek A: Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep, 2006, 58, Suppl, 81-88.
6. De Petrocellis L, Cascio MG, Di Marzo V: The endocannabinoid system: a general view and latest additions. Br J Pharmacol, 2004, 141, 765-774.
7. Després JP, Golay A, Sj-dsoström L: Rimonabant in Obesity-Lipids Study Group: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med, 2005, 353, 2121-2134.
8. Deedwania P: The endocannabinoid system and cardiometabolic risk: Effects of CB1 receptor blockade on lipid metabolism. Int J Cardiol, 2009, 131, 305-312.
9. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, Kunos G: Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem, 1999, 264, 258-267.
10. Di Marzo V, Petrosino S: Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol, 2007, 18, 129-140.
11. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005, 54, 2838-2843.
12. Gawaz M, Langer H, May AE: Platelets in inflammation and atherogenesis. J Clin Invest, 2005, 115, 3378-3384.
13. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab, 2004, 89, 2595-2600.
14. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep, 2008, 60, 3-11.
15. Hansson GK, Libby P: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 2006, 6, 508-519.
16. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H: The cannabinoid system and immune modulation. J Leukoc Biol, 2003, 74, 486-496.
17. Krysiak R, Okopień B: Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep, 2008, 60, 514-523.
18. Loverme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N et al.: Synthesis and characterization of a peripherally restricted CB(1) cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett, 2008, doi:10.1016/j.bmcl.2008.12.059.
19. Maccarrone M, Bari M, Menichelli A, Del Principe D, Finazzi Agrò A: Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett, 1999, 447, 277-282.
20. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi Agrò A: Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem, 2001, 268, 819-825.
21. Matias I, Di Marzo V: Endocannabinoids and the control of energy balance. Trends Endocrinol Metab, 2007, 18, 27-37.
22. 2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion, 2009, doi:10.1016/j.yjmcc.2008.12.014.
23. Nieswandt B, Aktas B, Moers A, Sachs UJ: Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost, 2005, 3, 1725-1736.
24. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP et al.: STRADI-VARIUS Investigators: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA, 2008, 299, 1547-1560.
25. Pacher P, Batkai S, Kunos G: Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol, 2005, 599-625.
26. Pacher P, Batkai S, Kunos G: Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology, 2005, 48, 1130-1138.
27. Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Liu J, Harvey-White J, Brassai A et al.: Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol, 2005, 289, H533-541.
28. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, 295, 761-775.
29. Randall MD, Kendall DA, O'Sullivan S: The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol, 2004, 142, 20-26.
30. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group: SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care, 2008, 31, 2169-2176.
31. Roth MD: Pharmacology: marijuana and your heart. Nature, 2005, 434, 708-709.
32. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T et al.: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol, 2007, 152, 1092-1101.
33. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet, 2006, 368, 1660-1672.
34. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M et al.: Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 2005, 434, 782-786.
35. 2+ influx via TRPV1 channels. Embo J, 2005, 24, 3026-3037.
36. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: RIO-Europe Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
37. 2 receptors. Science, 2005, 310, 329-332.
38. Wagner JA, Varga K, Jarai Z, Kunos G: Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension, 1999, 33, 429-434.
39. Weber C: Platelets and chemokines in atherosclerosis: partners in crime. Circ Res, 2005, 96, 612-616.
40. Woods SC: Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med, 2007, 120, S19-25.
41. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand, 1983, 67, 361-370.